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Introduction
Aldosterone production in the adrenal glomerulosa is directly stimulated by angiotensin II (Ang II), potassium and adrenocorticotropin (ACTH). The major signal transduction pathway for ACTH stimulation of aldosterone production occurs through cAMP-protein kinase A (PKA), while Ang II action is transduced by diacylglycerol-protein kinase C, inositol 1,4,5-trisphosphate/Ca 2+ signaling and mitogen-activated protein kinase (MAPK) via the Ang II type-I receptor (AT1R) [1] .
In the presence of these major stimulators, adrenocortical steroidogenesis is modulated by local autocrine/paracrine factors that reside in adrenal tissues [2] . Basic fibroblast growth factor, insulin-like growth factors, and transforming growth factor (TGF)-β1 have been postulated to play roles in the regulation of adrenal steroidogenesis [2] [3] [4] [5] . We previously reported the existence of a bone morphogenetic protein (BMP) and activin system consisting of specific type-I and -II receptors and Smads in adrenocortical cells [6] [7] [8] [9] .
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-6 -humans [17] [18] [19] [20] .
The circadian rhythms of melatonin and ACTH are inversely fluctuated.
In humans, melatonin secretion peaks at night and decreases in the daytime.
In contrast, circulating ACTH-cortisol peaks in the early morning and declines during the night. Interestingly, in Cushing's syndrome, which exhibits a lack of ACTH-cortisol secretory rhythm, the circadian change of melatonin was shown to be abnormal [21] . This finding implies that the increased melatonin at night plays a physiological role in suppression of ACTH-cortisol secretion or that excessive cortisol may lead to the abolishment of normal melatonin rhythm. It has been revealed that melatonin inhibits ACTH-induced cortisol production via MT1 expressed on the adrenals in various mammals [17, 19, 20] . Given that melatonin secretion can be abnormally lower at night and higher in the daytime in patients with Cushing's syndrome [21] , we assumed that the key circadian factor melatonin is involved in the pathogenesis of disturbed circadian changes in ACTH and cortisol.
Melatonin has been reported to suppress ACTH secretion in the SBMB-D-14-00384-R1 Hara, Otsuka, et al.
-7 -anterior pituitary and cortisol production in the adrenal by different mechanisms.
However, the effect of melatonin on aldosterone production, in comparison with cortisol changes, has remained unknown. In order to clarify the interaction between melatonin and adrenal steroidogenesis under the influence of ACTH,
we studied undefined roles of melatonin in the regulation of aldosterone production using human adrenocortical cells by focusing on the activin system.
- 
Results
First, the expression of melatonin receptor MT1 was detected in human adrenocortical H295R cells as well as in normal human adrenal tissue by RT-PCR (Fig. 1A) , whereas the expression of MT2 was not detected in H295R cells. Treatment with melatonin (10 to 1000 nM) did not affect basal levels of aldosterone or cortisol production (Fig. 1B, upper) in the medium for 24-h culture, and the ratio of aldosterone to cortisol production was not altered by melatonin (Fig. 1B, lower) . It was revealed that MT1 mRNA (Fig. 1C ) and MT1 protein ( Fig. 1D ) levels were upregulated by activin (100 ng/ml) for 24 h.
We next examined the effects of melatonin on Ang II-or ACTH-induced aldosterone production. Based on the results of our earlier studies regarding dose-and time-response actions of Ang II and ACTH [6-8], the cells were cultured in a medium containing Ang II (10 nM) or ACTH (100 ng/ml) for 24 h in the presence or absence of activin and melatonin. As shown in Fig. 2A , Ang II (10 nM) significantly increased aldosterone (~4 fold) and cortisol (~1.5 fold)
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-15 -production in the medium for 24-h culture, but treatment with activin alone (100 ng/ml) or in combination with melatonin (30 to 100 nM) had no significant effect on Ang II-induced production of aldosterone. The ratios of aldosterone/cortisol production induced by Ang II were not affected by treatment with activin (100 ng/ml), melatonin (30 to 100 nM), or their combination (Fig. 2B ).
As shown in Fig. 3A , ACTH (100 ng/ml) moderately, but significantly, increased aldosterone production (~1.5 fold) in 24-h cultured medium. In contrast to the effects on Ang II-induced aldosterone synthesis, melatonin treatment (30 nM) significantly augmented ACTH (100 ng/ml)-induced aldosterone synthesis in the presence of activin (100 ng/ml). The ratios of aldosterone/cortisol production were increased by activin effects (100 ng/ml), and the ratios induced by ACTH (100 ng/ml) were also significantly enhanced by melatonin (10 to 100 nM) in combination with activin (100 ng/ml) (Fig. 3B) .
Thus, activin increased ACTH-induced, but not Ang II-induced, aldosterone production. Notably, melatonin enhanced aldosterone production induced by co-treatment with ACTH and activin, although melatonin had no effect on
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-16 -aldosterone production stimulated by Ang II with activin ( Fig. 2A and 3A ).
These changes in steroidogenesis became apparent when evaluated by the ratios of aldosterone to cortisol (aldosterone/cortisol levels) ( Fig. 2B and 3B) .
Moreover, as shown in Fig. 3C , co-treatment with activin and melatonin enhanced aldosterone/cortisol levels stimulated by BtcAMP (0.1 and 1 mM) for 24 h, suggesting that the cAMP-PKA pathway is functionally involved in the upregulation of aldosterone production by activin and melatonin.
In accordance with the results for aldosterone production, ACTH (100 ng/ml) significantly increased cAMP synthesis by H295R cells for 24 h (Fig. 4A ).
Activin (100 ng/ml) tended to increase basal and ACTH-induced cAMP levels, though the effects were statistically insignificant. Of note, melatonin (30 nM) amplified ACTH-induced cAMP synthesis in the presence of activin (100 ng/ml) ( Fig. 4A ), in agreement with the data for aldosterone production induced by ACTH.
Furthermore, the expression levels of aldosterone synthase, CYP11B2, in comparison with 17α-hydroxylase, CYP17, were examined by real-time PCR
-17 -analysis. The level of CYP11B2 mRNA was moderately increased by ACTH (100 ng/ml) for 24-h culture, and the ACTH-induced increase in mRNA level was significantly augmented in the condition of co-treatment with activin (100 ng/ml) and melatonin (10 nM) (Fig. 4B, upper) . The level of CYP11B2/CYP17 mRNAs was increased by activin or ACTH treatment, and the ACTH-induced increase was significantly augmented by activin co-treatment ( Fig. 4B , lower). In accordance with the levels of aldosterone/cortisol production, the level of CYP11B2/CYP17 mRNAs stimulated by ACTH and activin was further enhanced in the condition of co-treatment with melatonin ( Fig. 4B, lower) . -18 -in the presence of ACTH (100 ng/ml). Of note, in the presence of melatonin action (30 nM), Smad2 phosphorylation induced by activin with ACTH was significantly enhanced (Fig. 5B) .
To further clarify the mechanism by which melatonin affected ACTH and activin signaling in H295R cells, mRNA levels of key receptors for ACTH and activin pathways were examined by real-time PCR analysis (Fig. 6) . Melatonin (30 nM) treatment for 24 h had no effect on ACTH-R expression (Fig. 6A) . The mRNA level of an activin type-I receptor, ALK-4, was significantly increased by melatonin (30 nM) (Fig. 6B) , while the mRNA levels of type-II receptors including
ActRIIA and ActRIIB were not significantly changed by melatonin (Fig. 6C) .
Interestingly, the mRNA levels of inhibitory Smads, Smad6 and Smad7, were significantly reduced by melatonin treatment for 24 h (Fig. 6D) , suggesting that melatonin facilitates Smad2 activation through downregulating inhibitory Smad6/7.
Thus, it was revealed that melatonin MT1 action enhanced aldosterone production induced by collaborating with ACTH and activin via the cAMP-PKA
-19 -pathway (Fig. 7) . In this mechanism, upregulation of MT1 as well as ALK-4 and downregulation of inhibitory Smad6/7 were functionally linked to the mutual enhancement of MT1 and activin-induced Smad2 signaling in adrenocortical cells.
Discussion
In the present study, we investigated the regulatory effects of melatonin on adrenocortical steroidogenesis using human adrenocortical cells. As shown in Activins and inhibins, which also belong to the TGF-β superfamily, are dimeric glycoproteins formed by two of three different subunits including α, βA, and βB. Expression of the activin system in human adrenal tissues and cells has been reported [25, 26] . In those studies, ACTH stimulated the production of inhibins through PKA signaling and decreased the ratio of activin/inhibin, leading to the hypothesis that a functional activin/inhibin system exists within the human adrenal cortex as a local regulator for ACTH signaling. Activin exerts its function by binding to ActRII and subsequent recruitment of ALK-4. In the present study, ALK-4 expression level was significantly increased by melatonin, although melatonin had no effect on ACTH-R expression in H295R cells. Upon -24 -of melatonin on ACTH-induced responses including cortisol and progesterone production and steroidogenic enzyme expression in the human adrenal gland [20] . It has also been demonstrated by using fetal rats that scheduled melatonin application can entrain adrenal gland rhythms [31] .
Based on these findings, we presumed that melatonin has extensive inhibitory effects on adrenal steroidogenesis including aldosterone production.
However, in the present study, it was revealed that melatonin rather upregulates aldosterone production induced by ACTH and activin via the cAMP-PKA pathway, which differed from the inhibitory effects on cortisol synthesis. These results suggest a possible crosstalk between melatonin signaling and activin receptor signaling in adrenocortical cells. Concerning the interrelationship between melatonin level and the hypothalamic-pituitary-adrenal axis, it is known that there is an aberrant mode of melatonin secretion in hypercortisolemic conditions such as Cushing's syndrome, implying that excessive cortisol may disturb the normal melatonin rhythm and vice versa. [36] showed that ACTH induces StAR expression. A steroid profiling revealed that H295R cells in a steady condition secrete cortisol predominantly, while aldosterone and other steroids are secreted at much lower levels [37] . On the other hand, it is notable that aldosterone output can be specifically activated in response to various stimuli such as ACTH and angiotensin II and, in particular, to potassium [37] , suggesting characteristics favorable to an in vitro model of hyperaldosteronism [37] . By utilizing this feature of H295R cells, it was uncovered that ACTH-induced cAMP-PKA activity is likely to be a key for upregulation of aldosterone production caused by activin and melatonin.
It has been, in general, recognized that H295R cells have a weak ACTH
There has been an accumulation of reports regarding the expressional and functional relationship between melatonin and TGF-β. For instance, it has SBMB-D-14-00384-R1 Hara, Otsuka, et al.
- 26 - been shown that melatonin increases TGF-β synthesis in human prostate epithelial cells, leading to melatonin-mediated attenuation of cell proliferation [38] . Inhibition of breast cancer cell proliferation by melatonin with vitamin D3 seems to be linked to activation of Smads [39] . Melatonin activates an osteogenic process by promoting the expression of BMP-2 and -4 via ERK and Wnt pathways [40] . We have also reported the effect of melatonin on regulation of ACTH production by corticotrope cells, in which MT1 and BMP-4 actions were mutually enhanced [23] . In ovarian granulosa cells, melatonin was shown to suppress BMP-6-induced Smad1/5/8 signaling by reducing Smad6 expression [24] . The BMP/activin system is a fine regulator of endocrine activity at various levels including the adrenal gland. Further research is needed to conclude whether melatonin is a functional clue for the integration of systemic aldosterone/cortisol balance in adrenal steroidogenesis.
Collectively, the results showed that melatonin facilitated aldosterone production induced by ACTH combined with activin via the cAMP-PKA pathway (Fig. 7) . The results also suggested a mutual interaction between melatonin were treated with activin for 60 min. A) The cell lysates were then subjected to SDS-PAGE/immunoblotting analysis using anti-pSmad2 and anti-tSmad2/3
antibodies. B) The integrated signal density of each protein band was digitally analyzed, and the ratios of signal intensities of pSmad2/tSmad2 were calculated.
Results are shown as means ± SEM. The results were analyzed by ANOVA.
The values with different superscript letters are significantly different at P < 0.05 (B). Results are shown as means ± SEM. The results were analyzed by the unpaired t-test. *, P < 0.05 vs. control groups. 
